Feedback / Questions
brazikumab (AMG 139) - AstraZeneca
Brazikumab: Data from P2 EXPEDITION trial (NCT03616821) for ulcerative colitis post 2024
(AstraZeneca)
-
Apr 27, 2023 -
Q1 2023 Results
P2 data
•
Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
https://www.astrazeneca.com/content/dam/az/PDF/2023/q1/Q1-2023-results-clinical-trials-appendix.pdf
Apr 27, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious